Financial Data and Key Metrics Changes - As of December 31, 2025, the company had $61.8 million in cash, cash equivalents, and marketable securities, reflecting a focus on cash preservation measures to enhance operational efficiency and extend runway [9][58]. Business Line Data and Key Metrics Changes - The company completed the randomized portion of the PALISADE-3 phase 3 trial in social anxiety disorder and is now focused on the ongoing PALISADE-4 trial, implementing refinements based on insights from PALISADE-3 [4][7]. - The open-label extension of PALISADE-3 and PALISADE-4 is ongoing, aimed at evaluating the safety and tolerability of fasedienol in real-world situations [6]. Market Data and Key Metrics Changes - The company is preparing to submit a US investigational new drug application for rafisolone, a hormone-free product candidate for treating moderate to severe vasomotor symptoms due to menopause, with a planned submission in the first half of 2026 [8][9]. Company Strategy and Development Direction - The company aims to deliver transformative treatments for social anxiety disorder and women's health, focusing on data-driven approaches and regulatory strategies that leverage the totality of evidence from its clinical programs [10]. - The strategic focus includes enhancing statistical models and understanding predictors of response to improve regulatory discussions with the FDA [5][7]. Management's Comments on Operating Environment and Future Outlook - Management emphasized the significant unmet need in social anxiety disorder and the commitment to advancing clinical programs that could provide meaningful value to patients and shareholders [10]. - The company is closely monitoring the evolving regulatory landscape, particularly the integration of AI in decision-making processes at the FDA [32]. Other Important Information - The company has implemented company-wide cash preservation measures to maintain strategic flexibility across its pipeline [9]. - Insights from ongoing studies are expected to contribute to a better understanding of fasedienol's drug effect and usage patterns [7]. Q&A Session Summary Question: Insights from PALISADE-3 data - The company is still analyzing the data from PALISADE-3 and has not released individual curves publicly, but differences have been noted in individual respondents and subgroups [12][13]. Question: Modifications to the SAP plan - Any future changes to the SAP would require resubmission and alignment with the FDA before database lock [18][20]. Question: Enrollment status for PALISADE-4 - Enrollment for PALISADE-4 has continued as planned and projected, with no impact observed since the announcement on December 17 [36][37]. Question: Regulatory path forward - The regulatory outcomes depend on the totality of data and the nature of the population in need, with a focus on the weight of evidence across the program [31][32]. Question: Impact of PALISADE-3 outcome on PALISADE-4 - The company is exploring potential covariates from previous studies that may influence the separation between treatment arms, but no guarantees can be made [38][39].

Bright Horizons Family Solutions (NYSE:BFAM) Q4 2025 Earnings call February 12, 2026 05:00 PM ET Speaker6Greetings, and welcome to the Bright Horizons Family Solutions fourth quarter 2025 earnings call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce Mich ...

Financial Data and Key Metrics Changes - In 2025, the company reported a record $4.3 billion in new transactions, an increase of 87% compared to 2024, with a growing pipeline exceeding $6.5 billion by year-end [4][5][9] - Adjusted EPS grew by 10.2% in 2025, reaching $2.70 per share, supported by increased investment volumes and profitability [5][16] - Adjusted ROE rose to 13.4%, reflecting a 70 basis point increase from 2024, driven by higher yields and growth in fees from managed assets [17][19] Business Line Data and Key Metrics Changes - The company closed over $3 billion in new investments excluding the $1.2 billion SunZia project, demonstrating strong underlying demand [7][8] - The investment volume retained on the balance sheet increased by approximately 140% year-over-year, totaling $3.6 billion in 2025 [8] - The portfolio yield improved to 8.8%, contributing to the overall earnings power of the managed assets, which grew by 18% to $16.1 billion [18][19] Market Data and Key Metrics Changes - The renewables pipeline is projected to exceed $230 billion, with renewables accounting for 99% of projected capacity additions in 2026 [10] - The demand for power and cost-effectiveness in asset classes have created an attractive investing environment, with PPA rates increasing over 40% in the past three years [9][10] - The company’s grid-connected business is benefiting from significant growth in renewables, particularly solar and storage [10] Company Strategy and Development Direction - The company aims to maintain a payout ratio below 50% by 2028, focusing on capital recycling to enhance growth and profitability [15][81] - The strategy includes expanding equity commitments in the CCH1 vehicle and enhancing capital efficiency through new funding sources [19][22] - The company is investing in talent and technology to support further scale and efficiency, with a focus on diverse asset classes [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving profitability objectives, with a three-year guidance extending to 2028, expecting adjusted EPS in the range of $3.50-$3.60 [14][25] - The operating environment remains favorable, with no significant negative or positive trends anticipated for 2026 [31][32] - Management highlighted the resilience of the business model despite challenges such as inflation and supply chain issues, maintaining a consistent growth trajectory [11][12] Other Important Information - The company achieved a record of 1.7 million metric tons in avoided CO emissions from new investments in 2025, contributing to a total of 10 million metric tons avoided to date [24] - The company has made significant investments in its platform, particularly in technology and talent, to position itself for future growth [25] Q&A Session Summary Question: Outlook for 2028 and growth above 10% CAGR - Management indicated that pathways to exceed 10% CAGR include increased volume, better yields, and lower debt costs [28][29] Question: 2026 outlook - Management noted that while they do not provide specific guidance for 2026, they expect meaningful growth based on the current pipeline [31][32] Question: Change in guidance strategy - The switch to nominal EPS guidance allows for more precise adjustments in future quarters, reflecting increased confidence in growth [38][39] Question: Investment opportunities and pipeline context - Management confirmed no structural change in the business, with larger investment opportunities emerging but no specific projects like SunZia currently in the pipeline [41][42] Question: Impact of PPA renegotiations on earnings - Positive renegotiations of PPAs are expected to enhance long-term cash flows and potentially accelerate EPS growth beyond current guidance [71][74]

Financial Data and Key Metrics Changes - Total revenue for 2025 was $249.3 million, with subscription revenue representing 53% of total revenue, up from 45% in 2024 [12][13] - In Q4 2025, total revenue was $55.3 million, a 22.1% year-over-year decline, with subscription revenue at $28.8 million, down 22% year-over-year [14][15] - Adjusted EBITDA for Q4 was a loss of $10.3 million, an improvement from a loss of $22.8 million in Q4 2024 [17] - Net loss for Q4 was $25.2 million, compared to $30.7 million in the previous quarter, representing a 43.5% improvement year-over-year [17] Business Line Data and Key Metrics Changes - Amwell Medical Group (AMG) visit revenue was $23.7 million, down 18.7% year-over-year, with paid AMG visits flat at approximately 340,000 [15] - Total platform visits were 1 million, down 28.4% year-over-year from 1.4 million visits in Q4 2024 [15] Market Data and Key Metrics Changes - The healthcare landscape is shifting towards operational efficiency, with payers and health systems pursuing platform consolidation and automation [3][4] - The Medicare population is aging, pharmacy costs are surging, and clinician shortages are worsening, driving demand for technology-enabled care [4][5] Company Strategy and Development Direction - The company has focused exclusively on offering a tech platform, enhancing patient engagement and reducing costs through automation and AI [6][9] - Amwell has divested non-core activities, such as the sale of APC, and restructured to reduce costs and improve revenue quality [10][11] - The company aims to achieve cash flow breakeven from operations in Q4 2026, with a focus on high-quality, sticky revenue [11][19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the impact of AI on healthcare and the company's role in integrating AI programs into a regulated infrastructure [26][29] - The company anticipates a strong secular trend towards technology-enabled care, with expectations for growth in both payer and government segments [44][46] Other Important Information - The company ended 2025 with approximately $182 million in cash and marketable securities and no debt [18] - For 2026, revenue is expected to be in the range of $195 million to $205 million, with AMG visits projected between 1.32 million and 1.37 million [18][19] Q&A Session Summary Question: What is the status of existing client contracts and government opportunities? - Management indicated that most contracts signed in 2025 were renewals, with significantly fewer open renewals in 2026, except for the DHA renewal expected in summer 2026 [22][23] Question: How does the company view the competitive landscape with new AI entrants? - Management is optimistic about AI's impact on healthcare and believes that their platform's ability to integrate multiple AI programs will provide a competitive advantage [25][27] Question: What are the headwinds and tailwinds for 2026 guidance? - Tailwinds include earlier adoption of the technology-enabled platform, while headwinds involve the upcoming DHA renewal [32][34] Question: Can you elaborate on the DHA revenue step down and potential recovery? - Management confirmed a step down in DHA revenue due to the elimination of certain programs but expressed confidence in the renewal and potential for additional revenue [35][36] Question: How does the company plan to resume growth in 2026? - Management emphasized the importance of their unified platform and the expected increase in usage across various care segments, particularly in government and payer markets [42][44]

Atomera (NasdaqCM:ATOM) Q4 2025 Earnings call February 12, 2026 05:00 PM ET Speaker1Hello everyone, and welcome to Atomera's fourth quarter and fiscal year 2025 update call. I'd like to remind everyone that this call and webinar are being recorded, and a replay will be available on Atomera's IR website for one year. I'm Mike Bishop with the company's investor relations. As in prior quarters, we are using Zoom, and we will follow a similar presentation format with participants in a listen-only mode. We will ...

Financial Data and Key Metrics Changes - For Q4 2025, the company reported revenue of $370 million, with an earnings per share (EPS) of $0.29, aligning with expectations [17][24] - For the full year 2025, adjusted EPS was $1.27, up from $0.84 in the previous year, representing a 51% growth [16][20] - Gross margin for Q4 was 70.7%, down from 71.4% in the prior year, while the core Nu Skin business gross margin improved to 77.6% [17][19] - The company generated $1.49 billion in revenue for the full year, with a foreign currency headwind of approximately $13.4 million [18][21] Business Line Data and Key Metrics Changes - The core Nu Skin business saw a gross margin of 77.4% for the full year, an 80 basis point improvement over the prior year [19] - Selling expenses for the core business were 40.3% for the year, with expectations to maintain around 40% moving forward [20] Market Data and Key Metrics Changes - The company initiated pre-market operations in India in November 2025, with a formal market opening anticipated in late 2026 [5][12] - Latin America continues to show strong performance, providing insights for expansion into new emerging markets [13][44] Company Strategy and Development Direction - The company aims to focus on the $6.8 trillion wellness market with the launch of the Prysm iO Intelligent Wellness Platform [6][15] - Strategic priorities include expanding into India and improving operational performance and efficiencies [12][15] - The company plans to place over 100,000 Prysm iO devices by the end of 2026, targeting 10 million healthy households by 2030 [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to growth by the end of 2026, despite inherent switching costs during the transition [5][15] - The company is cautious about revenue projections for India, focusing on establishing local infrastructure and logistics [35][36] - Management highlighted the importance of the Prysm iO launch in enhancing customer engagement and lifetime value [10][24] Other Important Information - The company ended the quarter with approximately $240 million in cash and reduced outstanding debt to $224 million, resulting in an expanded net cash position [21] - The company returned approximately $11.8 million in dividends and $20 million in share repurchases during the year [21] Q&A Session Summary Question: Insights on Prysm's revenue contribution - Management indicated that the placement of Prysm devices will lead to subscriptions, with an estimated market value of around $300 per device, potentially generating $30 million from device sales alone [32] Question: Thoughts on India market potential - Management sees long-term potential in India but is cautious about immediate revenue forecasts, focusing on local infrastructure and logistics [36][37] Question: Guidance considerations and leverage points - Management discussed modeling for 2026, emphasizing gross margin expansion and maintaining selling expenses around 40% [40][41] Question: Other portfolio performance insights - Management highlighted the restaging of the Tru Face skincare line and improvements in various markets, including China and Latin America [43][44]

XP (NasdaqGS:XP) Q4 2025 Earnings call February 12, 2026 05:00 PM ET Speaker0Good evening, everyone. I'm André Parize, Investor Relations Officer at XP. Thank you for joining us. It's a pleasure to be here with you today. On behalf of the company, I would like to welcome you to our fourth quarter 2025 earnings call. Today's presentation will be delivered by our CEO, Thiago Maffra, and our CFO, Victor Mansur. Both will be available for the Q&A session immediately afterwards. If you'd like to ask a question d ...

Maplebear (NasdaqGS:CART) Q4 2025 Earnings call February 12, 2026 05:00 PM ET Speaker11Good day, and thank you for standing by. Welcome to the Instacart Fourth Quarter 2025 financial results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear a message advising your hand is raised. To withdraw you ...

Financial Data and Key Metrics Changes - The company reported record total revenues of $219.0 million for the full year 2025, a 22% increase from $179.5 million in 2024, and Q4 total revenues of $62.4 million, up 25% year-over-year from $50.1 million [15][18] - Gross margin for Q4 was 77%, and operating margin was 24%, with full-year gross margin at 76% and operating margin at 21%, exceeding prior long-term targets [19][23] - Earnings per share (EPS) for the full year was $0.94, reflecting a 12% growth from $0.84 in the previous year [20] Business Line Data and Key Metrics Changes - Platform revenue for Q4 was $52.5 million, up 20% year-over-year, while volume-based revenue was $9.9 million, up 58% [16] - For the full year, platform revenue was $181.0 million, a 15% increase, and volume-based revenue was $38 million, up 70% [17] - Recurring revenue for Q4 was $61.1 million, up 62% year-over-year, and for the full year, it was $205.1 million, a 41% increase [17] Market Data and Key Metrics Changes - The semiconductor industry is projected to exceed $1 trillion in revenue, with increasing complexity in manufacturing processes driving demand for AI-driven collaboration [4][11] - The company anticipates continued growth in 2026, consistent with a long-term target of 20% CAGR, driven by increased customer activity and demand for AI solutions [12][23] Company Strategy and Development Direction - The company is transitioning from an analytics platform provider to an AI-driven collaboration platform, focusing on orchestration systems that align operational processes and data sharing [5][6] - The acquisition of secureWISE and the development of Exensio Studio AI are key components of the company's strategy to enhance its product offerings and market position [18][21] - The company aims to expand its platform across the industry, leveraging its secureWISE and Symmetrics products for equipment control and connectivity [12][23] Management's Comments on Operating Environment and Future Outlook - Management highlighted the accelerating need for AI-driven collaboration in the semiconductor industry, with expectations for increased customer activity in 2026 [11][12] - The company is optimistic about opportunities in advanced memory and characterization systems, anticipating nearly doubling the number of eProbe machines in the field [11][12] - Management expressed confidence in achieving revenue growth consistent with long-term targets, even without inorganic growth contributions [12][23] Other Important Information - The company ended 2025 with a backlog of $254 million and positive operating cash flow of approximately $24 million [18][21] - Capital expenditures for 2025 were approximately $33 million, primarily related to DirectScan systems, with expectations for similar spending in 2026 [21][23] Q&A Session Summary Question: DirectScan systems shipment and future expectations - The company confirmed that four DirectScan systems were shipped in 2025, with a total of six currently in the field, and plans to nearly double that number in the coming year [30][31] Question: Capital expenditure outlook - The company plans to manage capital expenditures evenly throughout 2026, with a focus on maintaining subscription models for machines [36][38] Question: SAP relationship and expectations - The partnership with SAP is progressing well, with increased needs for orchestration and automation, and the company expects to build on its installed base through this collaboration [40][42] Question: Balance sheet and debt management - The company is comfortable with its current debt levels and plans to prioritize cash generation and balance sheet health before significant debt repayment [45][49] Question: Revenue methodology and growth expectations - The company has broken down revenue into recurring and upfront categories to provide better visibility, with expectations for continued growth in volume-based revenue driven by secureWISE and other products [52][54]

Financial Data and Key Metrics Changes - Revenue for Q1 2026 was $15.5 million, a 39% increase from $11.1 million in the prior year [12] - Gross margins improved to 32.9%, up 240 basis points from 30.5% in the prior year [12] - Operating profit increased to $1.4 million from an operating loss of $0.2 million in the prior year [13] - Net profit for the quarter was $1 million, a significant increase from a net loss of $0.4 million in the prior year [13] - Adjusted EBITDA was $2 million, up 265% from $0.5 million in the prior year [14] - Positive cash flow from operations was $1.7 million, compared to cash used in operating activities of $0.3 million in the prior year [14] - Total debt increased to $27.3 million from $15.3 million in the prior year, with working capital debt decreasing to $10.9 million [15] Business Line Data and Key Metrics Changes - The core material handling vertical showed strong progress, with new OEM integrated high-voltage battery systems scheduled for commercial deliveries in March 2026 [6] - Robotics is viewed as a high-growth vertical, with commercial deliveries of modular 48-volt battery systems initiated in January [7] - Defense is expected to become a meaningful revenue contributor this fiscal year, with deliveries made to a global defense contractor [6] Market Data and Key Metrics Changes - The company established a Japanese subsidiary to support growing demands in Japan and the Asia Pacific region [8] - Demand trends in automation, robotics, and energy storage for data centers align with the company's core strengths [8] Company Strategy and Development Direction - The company aims to expand manufacturing capacity in Jamestown, New York, and develop next-generation products and technologies [6] - Plans to launch new products for Class Three material handling vehicles and next-generation software solutions at MODEX 2026 [10] - The company is focusing on energy storage systems for emerging 800-volt DC data center architectures [9] Management's Comments on Operating Environment and Future Outlook - Management expects to build on the momentum from Q1 and reaffirmed revenue guidance of 30% growth for fiscal 2026 [17] - The company is optimistic about the long-term opportunities in robotics and defense sectors [6][31] - Management acknowledged the potential for government programs to support growth in the defense sector [34] Other Important Information - The company raised gross proceeds of $28 million from an equity issuance to support engineering and R&D efforts [15] - The company is transitioning to a U.S. domestic filer under SEC rules, which may broaden the investor base and improve trading liquidity [17] Q&A Session Summary Question: Update on customer sales funnel velocity - The company has strong visibility from large Fortune 100 and 500 companies, with a pipeline of new customers at various stages of testing and ordering [20][22] Question: Progress on stationary storage project pilots - Pilots are scheduled for a government-backed project and internal testing before customer site deployment [26][27] Question: Expected revenue contribution from defense sector - Robotics is expected to be the second largest revenue driver, with defense also contributing significantly [31] Question: CapEx outlook for Jamestown facility - The company expects to spend 90% of the $50 million EXIM loan before the end of the fiscal year, with increased CapEx in Q2 and Q3 [53] Question: Revenue contribution from Jamestown facility - Cell manufacturing is anticipated to start in fiscal 2027, with some revenue from battery systems expected in fiscal Q4 2026 [57] Question: Impact of semiconductor costs - The company has not seen significant impacts from semiconductor costs, with the ability to adjust pricing if necessary [86]